Extract of Valerian Root (Valeriana Officinalis L.) vs. Placebo in Treatment of Obsessive-Compulsive Disorder: A Randomized Double-Blind Study

ArticleinJournal of Complementary and Integrative Medicine 8(1) · January 2011with60 Reads
DOI: 10.2202/1553-3840.1465 · Source: PubMed
Abstract
Obsessive-Compulsive Disorder (OCD) is a common neuropsychiatric condition. Many herbs with psychotropic effects exist which can have fewer side effects compared to more conventional medications. Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in the world with an effect on GABA. This plant is reported to be safe on humans. Our objective in this study was to compare the efficacy of the extract of Valeriana Officinalis L. with placebo in the treatment of OCD. The study was an 8-week pilot double-blind randomized trial. Thirty-one adult outpatients who met the DSM-IV-TR criteria for OCD based on the structured clinical interview participated in the trial. In this double-blind and randomized trial, patients were randomly assigned to receive either capsule of the extract (765 mg/day) or placebo (30 mg/day) for 8 weeks. The results showed significant difference between the extract and placebo in the end of treatment (P=0.000). Somnolence was the only significant difference between the two groups in terms of observed side effects (P=0.02). The results suggest that Valeriana Officinalis L. has some antiobsessive and compulsive effects. However, further studies are needed to confirm these findings. Psychiatrists often find that many patients cannot tolerate the side effects of psychiatry medicine Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in world with effect on GABA.The results showed significant difference between the extract and placebo in the treatment of OCD. There was also no significant difference between the two groups in terms of observed side effects.
    • "Neuroprotector: isquemia cerebral (Yoo et al. 2015), Parkinson (Oliveria et al. 2009). Ansiolítico (Werneke et al. 2006; Kennedy & Wightman 2011; Sharma et al. 2012), trastorno obsesivo-compulsivo (Pakseresht et al. 2011), estrés psicológico (Jung et al. 2014). Anticonvulsivo: epilepsia (Nsour et al. 2000; Quintans et al. 2011; TorresHernández et al. 2015). "
    [Show abstract] [Hide abstract] ABSTRACT: Recebido em agosto de 2015. Aceito em dezembro de 2015. Publicado em dezembro de 2015. ___________________________________________________________________________________________________________ RESUMEN – Este trabajo presenta resultados parciales de una línea de investigación en Etnobotánica urbana, desarrollada por el Laboratorio de Etnobotánica y Botánica Aplicada (LEBA) en el Área Metropolitana de Buenos Aires, Argentina. Se incluyen datos sobre 30 especies de plantas medicinales cuyos productos se comercializan como potenciadores cognitivos, vinculados con distintas condiciones neurológicas y psicológicas. Muchas de estas especies se emplean asimismo como adaptógenos. Se relevaron 145 sitios de expendio pertenecientes al circuito comercial general y al circuito restringido de dos segmentos de inmigrantes: boliviano y chino. Para cada especie se indican productos, muestras y usos asignados, con sus estudios de validación. La discusión contribuye a la comprensión de la complejidad del conocimiento botánico en los contextos pluriculturales urbanos, y a la dinámica de su transmisión sobre la base de la difusión de los productos relevados. PALABRAS CLAVE: Etnobotánica urbana, potenciadores cognitivos, adaptógenos, conocimiento botánico, Buenos Aires. ___________________________________________________________________________________________________________ THE BOTANICAL KNOWLEDGE IN URBAN AREAS: COGNITIVE ENHANCERS MARKETED IN THE METROPOLITAN AREA OF BUENOS AIRES, ARGENTINA ABSTRACT – This paper presents partial results of a research line on urban Ethnobotany, developed by the Laboratorio de Etnobotánica y Botánica Aplicada (LEBA) in the Metropolitan Area of Buenos Aires, Argentina. Data on 30 species of medicinal plants whose products are marketed as cognitive enhancers, linked to various neurological and psychological conditions are included. Many of these species are also used as adaptogens. 145 outlets belonging to general commercial circuit and the limited scope of two segments of immigrants (Bolivian and Chinese) were surveyed. Products, samples and assigned uses (with studies that validate them), are indicated for each species. The discussion contributes to the understanding of the botanical knowledge complexity in multicultural urban contexts and the dynamics of its transmission based on the diffusion of the products surveyed. KEY WORDS: Urban ethnobotany, cognitive enhancers, adaptogens, botanical knowledge, Buenos Aires. ___________________________________________________________________________________________________________ O CONHECIMENTO BOTÂNICO EM ÁREAS URBANAS: ESTIMULADORES COGNITIVOS COMERCIALIZADOS NA ÁREA METROPOLITANA DE BUENOS AIRES, ARGENTINA RESUMO-Este artigo apresenta resultados parciais de uma pesquisa em Etnobotânica urbana, desenvolvida pelo Laboratorio de Etnobotánica y Botánica Aplicada (LEBA) na Área Metropolitana de Buenos Aires, Argentina. São apresentados dados sobre 30 espécies de plantas medicinais, cujos produtos são comercializados como estimuladores cognitivos, ligados a várias condições neurológicas e psicológicas. Muitas destas espécies também são consumidas como adaptógenos. Cento e quarenta e cinco pontos de venda foram pesquisados, pertencentes ao circuito comercial geral e ao circuito restrito de dois grupos de imigrantes: bolivianos e chineses. Para cada espécie são indicados: produtos, amostras, e usos atribuídos com seus estudos de validação. A discussão ajuda a compreender a complexidade do conhecimento botânico em contextos multiculturais urbanos, e sua dinâmica de transmissão com base na difusão dos produtos pesquisados.
    Full-text · Article · Dec 2015 · Australian and New Zealand Journal of Psychiatry
    • "Neither kava nor valerian relieved anxiety or insomnia more than the placebo (Jacobs et al., 2005). More recently, pilot double blind RCTs with 33 patients with Obsessive Compulsive Disorder (OCD) showed a positive effect of valerian extracts on Young Mania Rating Scale (YMRS) score after eight weeks (Pakseresht et al., 2011). Most reviews have reported valerian to be a safe herb, and the only adverse event that occurs is daytime sedation at higher doses. "
    [Show abstract] [Hide abstract] ABSTRACT: Objectives: Patients with bipolar disorder frequently continue to experience residual anxiety and insomnia between mood episodes. In real-world practice, patients increasingly self-prescribe alternative medicines. Methods: We reviewed case reports, open-label, and placebo-controlled trials investigating the use of herbal medicines to treat anxiety and insomnia, and discussed their potential applications for bipolar disorder. Results: Eleven herbal medicines that have been studied in human subjects are included in this review. Mechanisms of action, efficacy, side effects, and drug-drug interactions are discussed. Based on currently available evidence, valerian seems to be the most promising candidate for insomnia and anxiety in bipolar disorder. Conclusions: Adjunctive herbal medicines may have the potential to alleviate these symptoms and improve the outcomes of standard treatment, despite limited evidence. Physicians need to have a more in-depth understanding of the evidence of benefits, risks, and drug interactions of alternative treatments.
    Full-text · Article · Jun 2014
    • "No significant differences were observed between experimental and control groups regarding side effects. However, no conventional drug was employed as control for comparison of effectiveness or safety in relation to placebo or treated groups [102]. In contrast, Andreatini et al. [103] reported that placebo, diazepam and the experimental group (treated with a mix of valepotriates constituted by 80% dihydrovaltrate, 15% valtrate and 5% acevaltrate-BYK-Gulden, Lomberg, Germany) had similar performances in relation to baseline or baseline change on scores of the most important parameters for detection of ameliorating GAD symptoms. "
    Full-text · Dataset · Apr 2014 · Australian and New Zealand Journal of Psychiatry
Show more

Recommended publications

Discover more